News Releases

Date Title and Summary View
August 2, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Aug. 2, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 7,000 shares of...
Additional Formats
July 19, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 19, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be...
Additional Formats
July 7, 2022
– Sebetralstat Phase 3 KONFIDENT and KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track – – Formal Notification Received of Sebetralstat EU Orphan Drug Status – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 7, 2022-- KalVista Pharmaceuticals, Inc....
Additional Formats
July 5, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 5, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted two newly-hired employees inducement options to purchase an aggregate of 8,000 shares of...
Additional Formats
July 5, 2022
– Sebetralstat data examines efficacy by attack location and population PK comparisons – – Preclinical data for oral Factor XIIa inhibitor shows durable suppression of kallikrein-kinin system - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jul. 5, 2022-- KalVista Pharmaceuticals, Inc....
Additional Formats
June 23, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 23, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of...
Additional Formats
June 8, 2022
– First preclinical data presented for structurally diverse oral Factor XIIa inhibitors - – Additional Sebetralstat data also presented - CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 8, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company...
Additional Formats
June 3, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 3, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 20,000 shares of...
Additional Formats
June 1, 2022
CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Jun. 1, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will be...
Additional Formats
May 27, 2022
– Patrick A. Treanor Appointed Effective Immediately – – Dan Soland Resigns in Planned Transition – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 27, 2022-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development,...
Additional Formats
Displaying 1 - 10 of 23